CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
Signal transduction for apoptosis or programmed cell death, after DNA damage in mammalian cells, is believed to involve activation of cyclin-dependent kinases (CDKs), especially CDK-1 (cdc2) and CDK-2. We used CDK-inhibitor olomoucine, a purine analogue to evaluate the role CDK inhibition on cytosine-arabinoside (Ara-C)-induced cell death. The two drugs showed an antagonistic effect, suggesting that apoptosis after exposure to Ara-C is inhibited by olomoucine. DNA-electrophoresis showed a clear inhibition of the apoptotic pattern when olomoucine was added to Ara-C. We conclude that CDK-inhibitor olomoucine inhibits cell death induced by Ara-C.
Papazisis
K T
KT
Theagenion Cancer Hospital, Thessaloniki, Greece. paptsi@med.auth.gr
Geromichalos
G D
GD
Kouretas
D
D
Dimitriadis
K A
KA
Kortsaris
A H
AH
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D003561:Cytarabine / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis; D053938:DNA Fragmentation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D007701:Kinetin; D011687:Purines / Q000494:pharmacology*; D015398:Signal Transduction
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D011687:Purines; D003561:Cytarabine; C090046:olomoucine; D004247:DNA; D018844:Cyclin-Dependent Kinases; D007701:Kinetin